Literature DB >> 17931123

Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels?

Peter J Anderson1, Stephen J Wood, Dorothy E Francis, Lee Coleman, Vicki Anderson, Avihu Boneh.   

Abstract

This study aimed to enhance our understanding of neuropsychological functioning in children with early-treated phenylketonuria (PKU) and assess the relative impact of white matter abnormalities (WMA) and neurotransmitter deficiencies on cognitive functions in this population. The study consisted of 33 children with early-treated PKU and 34 healthy control children aged between 7 to 18 years. All children had a neuropsychological evaluation that included measures of general intelligence, attention, processing speed, memory and learning, executive function, and academic achievement. Children in the PKU group also had a magnetic resonance (MR) brain scan. When compared with the control group, the PKU group exhibited global cognitive impairment including lower IQ, attention problems, slow information processing, reduced learning capacity, mild executive impairments, and educational difficulties. Children in the PKU group with extensive WMA (n = 14) displayed significant impairments across all cognitive domains. Metabolic control correlated weakly to moderately with attention, executive, and memory/learning factors. Within the PKU group, regressions revealed that executive function and attention factors were independently related to severity of WM pathology and age, while the memory and learning factor was independently related to metabolic control and age. It is concluded that children with early-treated PKU exhibit a global pattern of impairment, with a particular deficit in processing speed. WM pathology extending into frontal and subcortical regions correlates with the greatest deficits and a profile of impairment consistent with diffuse WM damage. Our findings also offer some support for dopamine depletion in the prefrontal cortex, however adverse consequences as a result of norepinephrine and serotonin deficiencies should not be discounted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17931123     DOI: 10.1080/87565640701375963

Source DB:  PubMed          Journal:  Dev Neuropsychol        ISSN: 1532-6942            Impact factor:   2.253


  38 in total

1.  Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria.

Authors:  Anna Hood; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desirée A White
Journal:  Mol Genet Metab       Date:  2014-01-31       Impact factor: 4.797

2.  The influence of blood phenylalanine levels on neurocognitive function in adult PKU patients.

Authors:  A Bartus; F Palasti; E Juhasz; E Kiss; E Simonova; Cs Sumanszki; P Reismann
Journal:  Metab Brain Dis       Date:  2018-06-12       Impact factor: 3.584

3.  Neuropsychological profile in parents of adult phenylketonuria patients.

Authors:  Gabriella Santangelo; Fausta Piscopo; Franco Santangelo; Luigi Trojano
Journal:  Neurol Sci       Date:  2017-11-09       Impact factor: 3.307

4.  Developmental Trajectories of Executive and Verbal Processes in Children with Phenylketonuria.

Authors:  Zoë W Hawks; Michael J Strube; Neco X Johnson; Dorothy K Grange; Desirée A White
Journal:  Dev Neuropsychol       Date:  2018-02-12       Impact factor: 2.253

5.  Neurocognitive phenotype of isolated methylmalonic acidemia.

Authors:  Colin J O'Shea; Jennifer L Sloan; Edythe A Wiggs; Maryland Pao; Andrea Gropman; Eva H Baker; Irini Manoli; Charles P Venditti; Joseph Snow
Journal:  Pediatrics       Date:  2012-05-21       Impact factor: 7.124

6.  Prolonged exposure to high and variable phenylalanine levels over the lifetime predicts brain white matter integrity in children with phenylketonuria.

Authors:  Anna Hood; Jo Ann V Antenor-Dorsey; Jerrel Rutlin; Tamara Hershey; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desiree A White
Journal:  Mol Genet Metab       Date:  2014-11-13       Impact factor: 4.797

7.  Cognitive and social profiles in two patients with cobalamin C disease.

Authors:  M H Beauchamp; V Anderson; A Boneh
Journal:  J Inherit Metab Dis       Date:  2009-10-15       Impact factor: 4.982

8.  Response monitoring in children with phenylketonuria.

Authors:  Gabriel C Araujo; Shawn E Christ; Robert D Steiner; Dorothy K Grange; Binyam Nardos; Robert C McKinstry; Desirée A White
Journal:  Neuropsychology       Date:  2009-01       Impact factor: 3.295

9.  Brain White Matter Integrity Mediates the Relationship Between Phenylalanine Control and Executive Abilities in Children with Phenylketonuria.

Authors:  Anna Hood; Jerrel Rutlin; Joshua S Shimony; Dorothy K Grange; Desiree A White
Journal:  JIMD Rep       Date:  2016-07-22

10.  White matter integrity and executive abilities in individuals with phenylketonuria.

Authors:  Jo Ann V Antenor-Dorsey; Tamara Hershey; Jerrel Rutlin; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Desirée A White
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.